fda vertex pharmaceuticals - Search News

FDA approves new pain medication

Hosted on MSN · 50m

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

MarketWatch · 7h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

USA TODAY on MSN · 1h

FDA approves new pain medication as an alternative to opioids: What to know about Journavx

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

1h

Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital

BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results